The Acute Myeloid Leukemia Channel is supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals.
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
EHA 2026 | Molecular profiling and MRD are reshaping transplant decision-making in AML
Arnon Nagler, MD, Chaim Sheba Medical Center, Tel-Aviv, Israel, discusses the growing importance of integrating molecular profiling and measurable residual disease (MRD) assessment into transplant decision-making for acute myeloid leukemia (AML). Prof. Nagler explains how genomic and MRD data are increasingly guiding risk stratification, transplant eligibility, and relapse monitoring in modern AML care. This interview took place at the 31st Congress of the European Hematology Association (EHA) in Stockholm, Sweden.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
